Navigation Links
Bioassociate Reiterated PT on RedHill Biopharma Following Q2 Report
Date:8/20/2013

TEL AVIV, Israel, August 20, 2013 /PRNewswire/ --

In a report published on July 29, Bioassociate reiterated a Buy rating on RedHill Biopharma (NASDAQ: RDHL) (TASE: RDHL), and maintained the ADS price target of $14.9. The report contains a detailed discussion of RedHill's pipeline advancements during the second quarter of 2013 and adjusted cash flows. The Q2 update valuation report is available at:

http://www.bioassociate.com/research-and-publications/publications/.

In the report, Bioassociate noted, "In the last quarter RedHill Biopharma has progressed its clinical programs in many aspects and is on schedule to achieve the 2013 goals. A February 3 2014 PDUFA date has been set for RHB-103, and an NDA submission of RHB-102 is expected during Q1 2014 as well. In addition, the R&D and regulatory paths for RHB-101 have been clarified by RedHill, with regulatory filling planned for H2 2014. Given the multiple milestones approaching and the company being on-track with the clinical programs' timelines, we reiterate our BUY recommendation and our target price of $14.9 per RedHill ADS."

About Bioassociate

Bioassociate is an independent investment research firm specialized in the life-science sector. Bioassociate helps inform readers about small-mid cap life science companies without extensive analyst coverage. Bioassociate structures its teams with multidisciplinary members to conduct specific assignments. The Bioassociate team has industry experience as well as consulting and research track record, providing investors with in-depth scientific insights and their financial manifestation.

Disclosure: 

The research report described in this press release is not constructed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer would be illegal. Bioassociate is not soliciting any action based upon this material. It does not take into account the particular investment objectives, financial situation, risk profile or other needs of individual investors. Before acting on any advice or recommendation in this material, an investor should consider whether it is suitable for his/her particular circumstances and, if necessary, seek professional advice. The report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should be relied upon as such. Opinions expressed are Bioassociate's current opinions as of the date appearing on this material only; such opinions are subject to change without notice. RedHilll is a client of Bioassociate and is paying Bioassociate a cash fee for Bioassociate's services, which include the preparation of equity research and valuation reports. The research report is based on public information and on information provided by RedHill, which according to RedHill is available publicly.  

Please read each report's full disclosures and analyst background on Bioassociate website, http://www.bioassociate.com, before investing. Bioassociate is not a registered investment adviser or broker-dealer.

The research report described in this press release contains forward-looking data subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking data represent Bioassociate's judgment as of the date of this release. Bioassociate disclaims, however, any intent or obligation to update this forward-looking data.

Contact:
info@bioassociate.com
+972-3-541-5050


'/>"/>
SOURCE Bioassociate
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
4. CeNeRx BioPharma Completes $4.85 Million Financing
5. PDL BioPharma Completes Regular Quarterly Dividend Payment
6. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
9. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
10. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
11. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Feb. 12, 2016 Biocom, the association representing the ... a group of San Diego companies ... its 2016 Precision Medicine Advocacy Fly-In. Biocom Fly-In participants had ... Drug Administration (FDA), the Centers for Medicare and Medicaid Services ... San Diego U.S. Representatives Susan Davis and ...
(Date:2/12/2016)... 12, 2016  PTC Therapeutics, Inc. (NASDAQ: ... (Strategies to Realize Innovation, Vision and Empowerment) grant ... provides funds to patient advocacy organizations to develop ... contributions to the rare disease community by increasing ... patient advocates. Mary Frances Harmon ...
(Date:2/11/2016)... -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial ... --> --> For the fourth ... million, or $0.34 loss per share, compared to a net loss ... period in 2014. For the year ended December 31, 2015, the ... per share, as compared to a net loss of $60.5 million, ...
(Date:2/11/2016)... -- Bioethics International, a not-for-profit organization focused on the ethics and ... accessible to patients around the world, today announced that the ... of the Good Pharma Scorecard an ,Editors, ... one of BMJ Open ,s ,Most Popular Articles, which ... frequently read. Ed Sucksmith , assistant editor of ...
Breaking Biology Technology:
(Date:1/20/2016)... Jan. 20, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce the ... achievements are the result of the company,s laser focus ... eClinical , it,s comprehensive, easy-to-use and highly affordable ... --> Key MedNet growth achievements in 2015 include: ...
(Date:1/18/2016)... JOSE, Calif. , Jan. 18, 2016 /PRNewswire/ ... security software that simplifies the use and access ... technology and go-to-market partnership with American Cyber.  ... Cyber brings extensive experience leading transformational C4ISR and ... implementing and integrating the latest proven technology solutions," ...
(Date:1/13/2016)... --> --> ... report titled - Biometric Sensors Market - Global Industry Analysis, ... to the report, the global biometric sensors market was valued at ... US$1,625.8 mn by 2023, expanding at a CAGR of ... the biometric sensors market is expected to reach 1,799.6 ...
Breaking Biology News(10 mins):